Randomized, Open Clinical Study to Evaluate the Protective Potential of EF192B Versus No Treatment

Eurofarma Laboratorios S.A.1 site in 1 country72 target enrollmentAugust 31, 2025

ConditionsSkin Lesions Skin Care

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Skin Lesions
Sponsor: Eurofarma Laboratorios S.A.
Enrollment: 72
Locations: 1
Primary Endpoint: Evaluate the effect of EF192B on the curative effect in the protection of small skin lesions through the formation of a barrier, showing its superiority versus no treatment (control) through transepidermal water loss 12 hours after its administration.
Status: Not yet recruiting
Last Updated: last year

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This study was designed with the objective of evaluating the protection potential provided by the experimental product EF192B by evaluating its barrier formation capacity. Once its ability to form a barrier is confirmed, EF192B ability to protect against small skin injuries, such as small cuts, bruises, blisters and cracks is confirmed. The barrier formation also guarantees protection against the formation of calluses.

Registry

clinicaltrials.gov

Start Date

August 31, 2025

End Date

October 31, 2025

Last Updated

last year

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Eurofarma Laboratorios S.A.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Outcomes

Primary Outcomes

Evaluate the effect of EF192B on the curative effect in the protection of small skin lesions through the formation of a barrier, showing its superiority versus no treatment (control) through transepidermal water loss 12 hours after its administration.

Time Frame: 12 hours

Secondary Outcomes

Efficacy of the EF192B in barrier formation, showing its superiority versus no treatment (control) through transepidermal water loss 12 hours after its administration.(12 hours)
Evaluate the efficacy of EF192B barrier formation through the range of transepidermal water loss 3 minutes, 6 hours, and 24 hours after its administration(24 hours)
Evaluate the efficacy of EF192B barrier formation through the range of corneometry 3 minutes, 6 hours, 12 hours, and 24 hours after its administration(24 hours)
Evaluate EF192B water resistance after four washes(12 hours)